A new form of gene therapy shows promise in battling recurrent brain cancer. The phase 1 clinical trial included 56 patients with recurrent high-grade glioma brain cancer. Three years after the gene therapy treatment, more than a quarter of the patients were still alive. Median survival for patients was 14.4 months, compared with eight months… Read More »
About AMS
Advanced Medical Strategies is an industry leader in delivering technology-driven solutions for payment integrity, risk management, and high dollar claims issues. Its predictive analytical software and decision support services help solve the critically important strategic problems of multiple stakeholders along the medical claims payment chain, those of which include commercial and governmental payers, Stop Loss and Reinsurance Carriers, MGUs, Medical Management Firms, Health Plans, TPAs, HMOs, Taft-Hartley Plans, workers compensation, and auto medical carriers.